​

Teva Pharmaceutical Industries (TEVA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TEVA Stock Forecast

Teva Pharmaceutical Industries (TEVA) stock forecast, based on 46 Wall Street analysts, predicts a 12-month average price target of $44.75, with a high of $48.00 and a low of $42.00. This represents a 21.44% increase from the last price of $36.85.

$10 $18 $26 $34 $42 $50 High: $48 Avg: $44.75 Low: $42 Last Closed Price: $36.85

TEVA Stock Rating

Teva Pharmaceutical Industries stock's rating consensus is Buy, based on 46 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 22 Buy (47.83%), 20 Hold (43.48%), 4 Sell (8.70%), and 0 Strong Sell (0.00%).

Buy
Total 46 0 4 20 22 Strong Sell Sell Hold Buy Strong Buy

TEVA Price Target Upside V Benchmarks

TypeNameUpside
StockTeva Pharmaceutical Industries21.44%
SectorHealthcare Stocks 15.45%
IndustrySpecialty & Generic Drug Manufacturers Stocks26.91%

Price Target Trends

1M3M12M
# Anlaysts3417
Avg Price Target$45.00$44.75$39.47
Last Closing Price$36.85$36.85$36.85
Upside/Downside22.12%21.44%7.11%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 26471--12
Aug, 2657---12
Jul, 2657---12
Jun, 2658---13
May, 26481--13
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 09, 2026Leerink Partners$45.00$36.7622.42%22.12%
Sep 04, 2026Ashwani VermaUBS$48.00$36.6231.08%30.26%
Aug 12, 2026Barclays$42.00$36.4815.13%13.98%
Jul 28, 2026David AmsellemPiper Sandler$44.00$31.0841.57%19.40%
May 06, 2026Barclays$40.00$35.8611.54%8.55%
Apr 30, 2026Piper Sandler$42.00$35.3818.71%13.98%
Apr 30, 2026UBS$42.00$35.3818.71%13.98%
Mar 04, 2026David AmsellemPiper Sandler$41.00$32.6425.61%11.26%
Jan 30, 2026Glen SantangeloBarclays$38.00$33.0714.91%3.12%
Jan 29, 2026Scotiabank$40.00$32.9021.58%8.55%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 04, 2026UBSBuyBuyhold
Aug 12, 2026BarclaysOverweightOverweighthold
Jul 20, 2026Piper SandlerOverweightOverweighthold
May 06, 2026BarclaysOverweightOverweighthold
Apr 30, 2026Piper SandlerOverweightOverweighthold
Apr 30, 2026UBSBuyBuyhold
Mar 04, 2026Piper SandlerOverweightOverweighthold
Feb 09, 2026Goldman SachsBuyBuyhold
Jan 30, 2026BarclaysOverweightOverweighthold
Jan 29, 2026ScotiabankOutperformOutperformhold

Financial Forecast

EPS Forecast

$-3 $-2 $-1 $0 $1 $2 $3 $4 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$0.38$-2.20$-0.50$-1.45$1.23--
Avg Forecast$2.54$2.52$2.32$2.48$2.73$2.97$2.99
High Forecast$2.60$2.61$2.41$2.53$2.95$3.29$3.10
Low Forecast$2.47$2.44$2.28$2.44$2.57$2.58$2.86
Surprise %-85.04%-187.30%-121.55%-158.47%-54.95%--

Revenue Forecast

$15B $15B $16B $17B $18B $19B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$15.88B$14.93B$15.85B$16.54B$17.26B--
Avg Forecast$16.07B$14.95B$15.39B$16.45B$17.05B$17.49B$16.94B
High Forecast$16.36B$15.37B$15.44B$16.52B$17.53B$18.34B$17.41B
Low Forecast$15.74B$14.58B$15.29B$16.41B$16.62B$16.63B$16.48B
Surprise %-1.18%-0.18%2.99%0.60%1.19%--

Net Income Forecast

$-3B $-1B $100M $1B $3B $4B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$417.00M$-2.45B$-559.00M$-1.64B$1.41B--
Avg Forecast$441.15M$406.30M$-559.00M$2.86B$3.18B$3.37B$3.43B
High Forecast$589.34M$553.53M$-356.45M$2.91B$3.40B$3.78B$3.57B
Low Forecast$292.95M$259.08M$-761.55M$2.80B$2.95B$2.97B$3.28B
Surprise %-5.47%-702.01%--157.41%-55.62%--

TEVA Forecast FAQ

Is Teva Pharmaceutical Industries stock a buy?

Teva Pharmaceutical Industries stock has a consensus rating of Buy, based on 46 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 22 Buy, 20 Hold, 4 Sell, and 0 Strong Sell, reflecting a consensus that Teva Pharmaceutical Industries is a favorable investment for most analysts.

What is Teva Pharmaceutical Industries's price target?

Teva Pharmaceutical Industries's price target, set by 46 Wall Street analysts, averages $44.75 over the next 12 months. The price target range spans from $42 at the low end to $48 at the high end, suggesting a potential 21.44% change from the previous closing price of $36.85.

How does Teva Pharmaceutical Industries stock forecast compare to its benchmarks?

Teva Pharmaceutical Industries's stock forecast shows a 21.44% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the specialty & generic drug manufacturers stocks industry (26.91%).

What is the breakdown of analyst ratings for Teva Pharmaceutical Industries over the past three months?

  • September 2026: 33.33% Strong Buy, 58.33% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 41.67% Strong Buy, 58.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 41.67% Strong Buy, 58.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Teva Pharmaceutical Industries’s EPS forecast?

Teva Pharmaceutical Industries's average annual EPS forecast for its fiscal year ending in December 2026 is $2.97, marking a 141.46% increase from the reported $1.23 in 2025. Estimates for the following years are.

What is Teva Pharmaceutical Industries’s revenue forecast?

Teva Pharmaceutical Industries's average annual revenue forecast for its fiscal year ending in December 2026 is $17.49B, reflecting a 1.33% increase from the reported $17.26B in 2025. The forecast for.

What is Teva Pharmaceutical Industries’s net income forecast?

Teva Pharmaceutical Industries's net income forecast for the fiscal year ending in December 2026 stands at $3.37B, representing an 139.31% increase from the reported $1.41B in 2025. Projections indicate .